Press release
Cirrhosis Clinical trials, Pipeline Analysis, EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, ROA, and Companies by DelveInsight
Cirrhosis Clinical trials
Key Takeaways from the Cirrhosis Pipeline Report
• DelveInsight's Cirrhosis pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Cirrhosis treatment.
• The leading companies working in the Cirrhosis Market include GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co., Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
• Promising Cirrhosis Pipeline Therapies in the various stages of development include NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, and others.
• On August 2023, Grifols Therapeutics LLC announced a study of Phase 3 Clinical Trials for Albutein 20% Injectable Solution. This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in subjects with decompensated cirrhosis and ascites.
• On September 2023, AstraZeneca announced a study of Phase 2 Clinical Trials for zibotentan (dose B) + dapagliflozin. This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.
Request a sample and discover the recent advances in Cirrhosis Treatment Drugs @ Cirrhosis Pipeline Report- https://www.delveinsight.com/report-store/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Cirrhosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Cirrhosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Cirrhosis clinical trial landscape.
Cirrhosis Overview
Cirrhosis is a late-stage liver disease characterized by extensive scarring (fibrosis) of liver tissue, which impairs its ability to function properly. It results from chronic liver damage caused by various conditions, including chronic alcohol abuse, hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), and autoimmune hepatitis. The healthy liver tissue is progressively replaced by scar tissue, obstructing blood flow through the liver and diminishing its essential functions, such as detoxifying harmful substances, producing blood-clotting proteins, and regulating nutrients.
Symptoms of cirrhosis often emerge gradually and can include fatigue, jaundice (yellowing of the skin and eyes), easy bruising, itching, swelling in the legs and abdomen (edema and ascites), and confusion due to the buildup of toxins in the blood (hepatic encephalopathy). Advanced cirrhosis can lead to life-threatening complications like portal hypertension, esophageal varices, and liver cancer.
Diagnosis involves a combination of medical history, physical examination, blood tests, imaging studies, and sometimes liver biopsy. Treatment focuses on managing symptoms, slowing disease progression, and addressing underlying causes. Lifestyle changes, such as abstaining from alcohol and following a healthy diet, are crucial. In severe cases, liver transplantation may be necessary. Early detection and ongoing medical care are vital to improving outcomes for individuals with cirrhosis.
Find out more about Cirrhosis Treatment Landscape @ Drugs for Cirrhosis Treatment- https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Cirrhosis Emerging Drugs Profile
• GXHPC 1: GWOXI Stem Cell Applied Technology
• LPCN 1148: Lipocine
• Belapectin: Galectin Therapeutics
Cirrhosis Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Cirrhosis. The Cirrhosis companies which have their Cirrhosis drug candidates in the most advanced stage, i.e. phase II/III include, Galectin Therapeutics.
Learn more about the emerging Cirrhosis Pipeline Therapies @ Cirrhosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Cirrhosis Pipeline Report
• Coverage- Global
• Cirrhosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cirrhosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cirrhosis Companies- GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co., Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
• Cirrhosis Pipeline Therapies- NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, and others.
Dive deep into rich insights for new drugs for Cirrhosis Treatment, Visit @ Cirrhosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Cirrhosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cirrhosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase II/III)
8. Belapectin: Galectin Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GXHPC 1: GWOXI Stem Cell Applied Technology
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cirrhosis Key Companies
21. Cirrhosis Key Products
22. Cirrhosis- Unmet Needs
23. Cirrhosis- Market Drivers and Barriers
24. Cirrhosis- Future Perspectives and Conclusion
25. Cirrhosis Analyst Views
26. Cirrhosis Key Companies
27. Appendix
Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cirrhosis Clinical trials, Pipeline Analysis, EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, ROA, and Companies by DelveInsight here
News-ID: 3830899 • Views: …
More Releases from DelveInsight Business Research
Autism Spectrum Disorders Market Set for Transformative Growth as Novel Treatmen …
The Autism Spectrum Disorder (ASD) market is projected to grow steadily from 2024 to 2034, driven by rising awareness, improved diagnostic practices, and ongoing advancements in therapeutic development. Currently, major pharmaceutical companies such as Otsuka, Johnson & Johnson, and Flynn Pharma dominate the market with approved treatments including ABILIFY, RISPERDAL, and SLENYTO. Market expansion is expected as emerging therapies - developed by companies like MapLight Therapeutics, Hoffmann-La Roche, Axial Therapeutics,…
Hutchinson-Gilford Progeria Syndrome Market Poised for Strong Growth Through 203 …
DelveInsight's "Hutchinson-Gilford Progeria Syndrome (HGPS) Market Insights, Epidemiology, and Market Forecast-2032" report provides a comprehensive analysis of Hutchinson-Gilford Progeria Syndrome, including historical and projected epidemiological trends, as well as market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
This latest healthcare forecast offers an in-depth evaluation of the HGPS landscape-covering prevalence patterns, revenue trends, and the evolving treatment ecosystem. It highlights key statistics on…
Fuchs Dystrophy Clinical Trial Assessment 2025: Over 5 Global Companies Accelera …
The Fuchs Dystrophy Pipeline Insight 2025 report delivers a comprehensive commercial and clinical evaluation of pipeline candidates, ranging from preclinical research to marketed therapies. It provides detailed drug profiles covering mechanisms of action, clinical trial updates, regulatory milestones (including NDAs where applicable), and ongoing development activities such as partnerships, funding, acquisitions, and technology platforms.
The report offers an in-depth overview of the current clinical landscape and the future growth outlook of…
Lymphangioleiomyomatosis Market Set for Significant Growth Through 2032, Reveals …
DelveInsight's "Lymphangioleiomyomatosis Market Insights, Epidemiology, and Market Forecast-2032" provides a comprehensive evaluation of Lymphangioleiomyomatosis (LAM), covering historical and projected epidemiology, market trends, and therapeutic dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
This latest healthcare market forecast delivers an in-depth assessment of Lymphangioleiomyomatosis, including revenue trends, disease prevalence, and the evolving treatment landscape. It highlights current and future market size estimates, evaluates emerging therapies,…
More Releases for Cirrhosis
Cirrhosis Pipeline: Novel Antifibrotic Therapies and Regenerative Approaches Red …
The treatment landscape for cirrhosis, a progressive liver condition marked by fibrosis and compromised liver function, is witnessing a transformative shift as biopharmaceutical companies advance beyond symptomatic management to target the underlying causes of liver damage. With no approved therapies to reverse established fibrosis, there is a growing focus on antifibrotic agents, hepatoprotective compounds, and regenerative therapies that aim to halt or reverse disease progression. Companies like Ocera Therapeutics, Gilead…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known as fibrosis as a result of liver disease damage. Cirrhosis is caused by alcoholic liver disease, non-alcoholic steatohepatitis (NASH), chronic hepatitis B, and chronic hepatitis C.
To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31149
Cirrhosis symptoms emerge slowly until liver…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about Primary Biliary Cirrhosis - Drug Pipeline here: https://www.globalinsightservices.com/reports/primary-biliary-cirrhosis-primary-biliary-cholangitis-drug-pipeline-landscape-2022/
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Liver Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about this report: https://www.globalinsightservices.com/reports/liver-cirrhosis-drug-pipeline-landscape-2023/
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually.
Read more about Primary Biliary Cirrhosis - Drug Pipeline…
Global Liver Cirrhosis Market Growth 2018-2023
Market Research Report Store offers a latest published report on Liver Cirrhosis Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Liver Cirrhosis players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Liver Cirrhosis with respect to individual…
